| 通報(bào)號: G/TBT/N/CAN/468 |
ICS號: 11.120
|
發(fā)布日期: 2015-10-08
|
截至日期: 2015-10-08
|
通報(bào)成員: 加拿大
|
目標(biāo)和理由: 保護(hù)人類安全和健康
|
| 內(nèi)容概述: 本評議通知的目的是提供機(jī)會(huì)，評議通過修訂人用處方藥清單（PDL）將埃索美拉唑的某些用途轉(zhuǎn)變?yōu)槿擞梅翘幏剿幍奶岚浮?br /> |
正文:
| 世界貿(mào)易組織 |
G/TBT/N/CAN/468
2015-10-08
15-5234
|
| |
| 技術(shù)性貿(mào)易壁壘 |
原文：英語/法語
|
通 報(bào)
以下通報(bào)根據(jù)TBT協(xié)定第10.6條分發(fā)
| 1. |
通報(bào)成員: 加拿大
如可能，列出涉及的地方政府名稱 ( 3.2條和7.2 條)：
|
| 2. |
負(fù)責(zé)機(jī)構(gòu):衛(wèi)生部
|
| 3. |
通報(bào)依據(jù)條款:
[ ] 2.9.2
[ ] 2.10.1
[ ] 5.6.2
[ ] 5.7.1
通報(bào)依據(jù)的條款其他：
|
| 4. |
覆蓋的產(chǎn)品： 人用處方藥藥物成分。其它。 ICS: 11.120 HS: 3004.90、300490
HS編碼:300490 ICS編碼:11.120
|
| 5. |
通報(bào)標(biāo)題： 評議通知－處方藥清單（PDL）：埃索美拉唑
語言：英語和法語 頁數(shù)：2 鏈接網(wǎng)址：
|
| 6. |
內(nèi)容簡述： 本評議通知的目的是提供機(jī)會(huì)，評議通過修訂人用處方藥清單（PDL）將埃索美拉唑的某些用途轉(zhuǎn)變?yōu)槿擞梅翘幏剿幍奶岚浮?/div>
|
| 7. |
目標(biāo)與理由:保護(hù)人類健康安全
|
| 8. |
|
| 9. |
擬批準(zhǔn)日期:-
擬生效日期:-
[ ] 通報(bào)日后6個(gè)月，及/或(年月日)： 2015/12/16 [ ] 貿(mào)易促進(jìn)措施
|
| 10. |
意見反饋截止日期：
[ ] 通報(bào)發(fā)布日起60天，及/或(年/月/日):
|
| 11. |
文本可從以下機(jī)構(gòu)得到:
[ ] 國家通報(bào)機(jī)構(gòu)
[ ] 國家咨詢點(diǎn)，或其他機(jī)構(gòu)的聯(lián)系地址、傳真及電子郵件地址(如能提供):
|
|
正文(英):
NOTIFICATION
The following notification is being circulated in accordance with Article 10.6
|
1.
|
Notifying Member: Canada
If applicable, name of local government involved (Article 3.2 and 7.2):
|
|
2.
|
Agency responsible: Department of Health
Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:
Canada's Notification Authority and Enquiry Point
Foreign Affairs, Trade and Development Canada
Technical Barriers and Regulations Division (TIB)
111 Sussex Drive
Ottawa, ON K1A 0G2
Canada
Telephone: (343) 203-4273
Fax: (613) 943-0346
Email: enquirypoint@international.gc.ca
|
|
3.
|
Notified under Article 2.9.2 [X], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], other:
|
|
4.
|
Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable): Prescription status of medicinal ingredients for human use (ICS: 11.120; HS: 3004.90). – Other (HS: 300490)
|
|
5.
|
Title, number of pages and language(s) of the notified document: Notice of Consultation ? Prescription Drug List (PDL): Esomeprazole (2 pages, in English and French)
|
|
6.
|
Description of content: The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to switch certain uses of Esomeprazole to non?prescription status for human use by modifying the Human Prescription Drug List (PDL).
|
|
7.
|
Objective and rationale, including the nature of urgent problems where applicable: Protection of human health or safety
|
|
8.
|
Relevant documents: Health Canada website: http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_esomeprazole-eng.php, posted: 2 October 2015 (available in English and French)
|
|
9.
|
Proposed date of adoption: ?
Proposed date of entry into force: ?
|
|
10.
|
Final date for comments: 16 December 2015
|
|
11.
|
Texts available from: National enquiry point [X] or address, telephone and fax numbers and email and website addresses, if available, of other body:
The electronic version of the notice can be downloaded at:
http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_esomeprazole-eng.php
http://www.hc-sc.gc.ca/dhp-mps/consultation/drug-medic/lead_pdl_ldo_consult_esomeprazole-fra.php
|
|
| |
|
| |
|
|
|
本網(wǎng)維權(quán)及免責(zé)聲明：
①凡本網(wǎng)所有原始/編譯文章及圖片、圖表的版權(quán)均屬江蘇省技術(shù)性貿(mào)易措施信息平臺（www.tbtguide.com)所有，如要轉(zhuǎn)載，需注明"信息來源：江蘇省技術(shù)性貿(mào)易措施信息平臺"或"信息來源：tbtguide"。違反上述規(guī)定者，本網(wǎng)將保留追究其侵權(quán)責(zé)任的權(quán)利。
②凡本網(wǎng)注明"信息來源：XXX（非tbtguide）"的作品，均轉(zhuǎn)載自其他媒體，轉(zhuǎn)載目的在于傳遞更多的信息，并不代表本網(wǎng)贊同其觀點(diǎn)和對其真實(shí)性負(fù)責(zé)。
聯(lián)系E-mail：js_wto@163.com |
京公網(wǎng)安備11010802046783號
